TiGenix reports positive top-line results from Phase III trial of Cx601 for perianal fistulas

Belgium-based biopharmaceutical company TiGenix has reported positive top-line week 104 results from the Phase III clinical trial (ADMIRE-CD) of Cx601 for the treatment of complex perianal fistulas in patients with Crohn's disease.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news